HOUSTON, Texas -- CytoGenix Inc. announces that its researchers have identified and tested an anti-sense oligonucleotide sequence that will kill Staphylococcus aureus bacteria including vancomycin-resistant (VRSA) and methicillin-resistant (MRSA) strains. This achievement is part of CytoGenix's ongoing research and development program for a new generation of antimicrobial compounds designed to defeat the bacteria's natural defenses.
Infection by the new strains of resistant staph is a growing public health problem. The Centers for Disease Control and Prevention (CDC) reports, "Staph bacteria are one of the most common causes of skin infection in the United States, and are a common cause of pneumonia and bloodstream infections ... as many as 100,000 persons are hospitalized each year with MRSA infections, although only a small proportion of these persons have disease onset occurring in the community."
Johns Hopkins AIDS Service reports, "The emergence of CA-MRSA infections is an additional threat to the growing global public health crisis of antimicrobial resistance. Efforts to control MRSA infections can no longer depend solely on surveillance, infection control efforts, and judicious antibiotic prescribing practices within the hospital setting. Proactive patient education, aggressive diagnostic efforts, and effective treatment for CA-MRSA infections by outpatient clinicians, will not only improve patient care, but also protect our communities and hospitals from an increasingly prevalent pathogen."
Dr. Malcolm Skolnick, CytoGenix president and CEO, commented, "We continue to focus our scientific assets on addressing significant unmet medical needs such as multi-drug resistant bacterial infections. In 2005, we plan to accelerate the pace of drug discovery and product development of this and other antimicrobial compounds.
"We are at the point that by using our proprietary genomic techniques, we can screen for gene targets and develop effective compounds to inhibit disease-causing activity in a matter of months rather than the years required for traditional drug discovery. For this reason we have been able to readily isolate several lead drug candidates against these resistant bacteria strains," adds Skolnick.
CytoGenix Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. CytoGenix currently has one issued U.S. patent and 37 international or U.S. pending patent applications claiming methods and materials in connection with this platform technology.
Source: CytoGenix Inc.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.